SJR76 Alabama 2014 Session

Updated Feb 27, 2026

Notable

Summary

Primary Sponsor: Dick Brewbaker
Republican
Co-Sponsors: Bill Holtzclaw Rodger Smitherman Paul Bussman Cam Ward Rusty Glover Linda Coleman-Madison Bryan Taylor Del Marsh Vivian Davis Figures Clay Scofield Bill Hightower Gerald O. Dial Greg J. Reed Bobby D. Singleton
Session: Regular Session 2014
Title: Muscular Dystrophy, Duchenne, Food and Drug Administration urged to grant accelerated approval for the drug eteplirsen for treatment
Summary: Alabama's SJR76 urges the FDA to grant accelerated approval for eteplirsen to treat Duchenne muscular dystrophy.
What This Bill Does
The resolution expresses support for eteplirsen and asks the FDA to accept and quickly review its application under the FDASIA accelerated approval pathway, aiming to make the drug available to more patients while further testing continues. It also notes the goal of speeding access without finished testing and review halting. It requires copies of the resolution to be sent to the FDA Commissioner and Alabama's Congressional Delegation.

Who It Affects
Duchenne muscular dystrophy patients and their families in Alabama, who could gain earlier access to eteplirsen if accelerated approval is granted.
The FDA and the drug sponsor/developer of eteplirsen, who would be urged to pursue and expedite the accelerated approval process.

Key Provisions
Urges the FDA to accept and promptly review eteplirsen under the accelerated approval pathway provided by FDASIA.
Requires that copies of the resolution be provided to the FDA Commissioner and to Alabama's Congressional Delegation.

AI-generated summary using openai/gpt-5-nano on Feb 25, 2026. May contain errors — refer to the official bill text for accuracy.
Subjects: Resolutions, Legislative